Acrux Secures AUD 5.4 Million Milestone Deal for Lenzetto in Australia
Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.
- Licensing deal with milestone payments up to AUD 5.4 million
- Upfront, regulatory, and commercial milestones structured for payments
- Gedeon Richter to handle TGA registration in Australia
- Milestones linked to TGA approval and sales or two-year post-launch
- Deal strengthens Acrux’s foothold in Australian hormone therapy market
Milestone Payments Structure for Lenzetto® Licensing
Acrux Limited (ASX:ACR) has formalised a milestone-based licensing agreement for its estradiol spray Lenzetto® in Australia, potentially unlocking up to AUD 5.4 million in payments. The deal’s payment schedule is split into three key milestones: an upfront signing fee payable within two weeks of the amendment’s execution, a regulatory milestone contingent on Therapeutic Goods Authority (TGA) marketing authorisation, and a commercial milestone triggered either by cumulative sales targets or two years after product launch.
Regulatory and Commercial Responsibilities
Gedeon Richter Plc will take charge of registering Lenzetto® with the TGA, a critical step before the regulatory milestone payment is due. This delegation underscores Acrux’s strategy of leveraging established partners for market entry, allowing it to focus on product development and broader commercialisation efforts. The commercial milestone is structured to align Acrux’s revenue with real-world sales performance or a timeline safeguard, whichever occurs first.
Strategic Importance for Australian Market Entry
This licensing deal addresses a notable gap in the Australian menopause hormone therapy sector, positioning Lenzetto® to capture unmet demand. The product’s Patchless Patch™ delivery technology has already seen success in over 40 countries, generating EUR 50 million in sales in 2025. The agreement not only provides Acrux with a clear revenue pathway but also strengthens its presence in a market where hormone therapy shortages have been reported. This milestone deal builds on the company’s recent strategic moves, including a $1.6 million placement to back female testosterone trials and efforts to expand its hormone therapy portfolio.
Financial and Market Implications
The milestone payments offer Acrux a phased revenue stream that mitigates upfront risk while aligning incentives with regulatory success and market uptake. The timing and certainty of these payments remain dependent on regulatory approval timelines and commercial performance, factors that introduce some variability into near-term cash flow expectations. Nonetheless, the deal enhances Acrux’s financial outlook amid ongoing development of its female testosterone therapy and other pipeline initiatives.
Bottom Line?
Acrux’s milestone deal for Lenzetto® provides a structured revenue opportunity tied to regulatory and sales success, setting a clear path for growth in the Australian hormone therapy market.
Questions in the middle?
- How quickly will Gedeon Richter secure TGA approval for Lenzetto®?
- What sales trajectory will trigger the commercial milestone within two years?
- Could this deal influence Acrux’s strategic focus on hormone therapies beyond Australia?
